Mostrar Notícias:

SEPRPrincipaisÚltima HoraBovespa - Brasil

 Ver notícias de outros activos

Pesquisa de notícias relativas à acção Sepracor Inc. (ordenadas pela data):

Allergy Treatment Market Research Report: Quantitative Market Analysis, Current and Future Trends, 2024 Digital Journal ... Meda Pharmaceuticals, Inc., Allergan plc, Schering-Plough Corporation, Alerpharma S.A., McNeil Consumer Healthcare, Allergopharma, Genentech, Inc., Allergon AB, Collegium Pharmaceutical, Inc., and Sepracor, Inc. These companies have been looking ... e mais »

Allergy Treatment Market : Trends, Outlook and Opportunity Analysis 2024 Digital Journal ... Meda Pharmaceuticals, Inc., Allergan plc, Schering-Plough Corporation, Alerpharma S.A., McNeil Consumer Healthcare, Allergopharma, Genentech, Inc., Allergon AB, Collegium Pharmaceutical, Inc., and Sepracor, Inc. These companies have been looking ...

Flex Pharma (FLKS) Names William McVicar President and cEO StreetInsider.com ... Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases including multiple sclerosis (MS), Charcot-Marie-Tooth (CMT ... e mais »

Flex Pharma Reports Second Quarter 2017 Financial Results Business Wire (press release) The INC is an integrated group of academic medical centers, patient support organizations, and clinical research resources dedicated to conducting clinical research in CMT and to improving the care of patients (www.rarediseasesnetwork.org/cms/inc ... e mais »

Desloratadine Market Key Players, Industry Overview, Supply and Consumption Demand Analysis to 2021 satPRnews (press release) Desloratadine Market Key Players Analysis: Pfizer, Teva, Wante Pharmaceutical?, Novartis India Limited, Mylan, Sepracor, Sandoz, Apollo Pharmaceuticals, GSK, Mayne Pharma Inc, Abhilasha Pharma Pvt, Abbott, Takeda, Schering-Plough, Nanjing Hicin ...

Frequency Therapeutics Announces its Board of Directors and the Appointment of Marc A. Cohen as Chairman Yahoo Finance The Board Members include Tim Barberich, founder and former CEO and Chairman of Sepracor, Inc. (now known as Sunovion), Marc Kozin, Senior Advisor and former President of L.E.K. Consulting, Robert S. Langer, Sc.D., Frequency Co-founder and the ... e mais »

Flex Pharma Names William K. McVicar, Ph.D. as President, Research & Development Business Wire (press release) Flex Pharma, Inc. (NASDAQ: FLKS), focused on developing treatments for cramps and spasms associated with severe neurological diseases, today announced the appointment of William K. McVicar, Ph.D., as President of Research and Development. ... ?With ... e mais »

PR Newswire (press release)

Genzyme Corporation Pays $5.885 Million To Resolve False Claims Act Allegations; Judgment Involving Cases ... PR Newswire (press release) Those defendants include Allergan, Inc., Amgen, Inc., Bradley Pharmaceuticals, Inc., Eisai, Inc., Mallincrodt, Inc., Novo Nordisk, Inc., Reliant Pharmaceuticals, Inc., Sepracor, Inc., and Upsher-Smith Laboratories, Inc. The settlement with Genzyme ... e mais »

Rewire

Religious Imposition Proponents Find an Ally in the White House Rewire Stirrup worked as a senior legislative adviser at Venable LLP from 2003 to 2008. The firm's clients between those years included AstraZeneca Pharmaceuticals, Sepracor Inc, and the National Association of Spine Specialists. Another hire, Anna Pilato, is ...

TheChronicleHerald.ca (registration)

PEI's BioVectra buys former Sepracor plant in Windsor TheChronicleHerald.ca (registration) A Charlottetown drug manufacturer has acquired a mothballed Windsor pharmaceutical plant and plans to reopen the facility in early 2016. BioVectra Inc. purchased the former Sepracor Canada (Nova Scotia) Ltd. facility in May. The Sepracor operation ... Charlottetown's BioVectra expanding, setting up in WindsorHants Journal todos os 5 artigos de notícias »

Reuters

Dainippon to buy US drug firm Sepracor for $2.6 billion Reuters BOSTON/TOKYO (Reuters) - Dainippon Sumitomo Pharma Co Ltd agreed on Thursday to buy U.S. drugmaker Sepracor Inc for $2.6 billion, giving the Japanese firm a big, local sales force in the world's largest drugs market. The deal is the latest in a string ...

Sunovion Enters Agreement to Divest Asthma and Allergy Products to Covis Pharma Digital Journal MARLBOROUGH, Mass.--(Business Wire)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it has entered into a definitive agreement to divest the U.S. market rights to Sunovion's ciclesonide products ALVESCO® (ciclesonide) Inhalation ...

Sunovion Pharmaceuticals Inc. Announces Company Name Change Business Wire (press release) BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion), formerly Sepracor Inc. (Sepracor), announced today that it has formally changed its name. The change occurs on approximately the one year anniversary of the acquisition of Sepracor by ... e mais »

RXi Pharmaceuticals Announces Closing of $11.5 Million Underwritten Public Offering and Full Exercise of Over ... PR Newswire (press release) Sc. and Chief Development Officer, Pamela Pavco, Ph.D. Other participants included OPKO Health, Inc. (NASDAQ: OPK), an existing investor of RXi, and Timothy Barberich, co-founder of MirImmune, Inc. and former CEO and Chairman of Sepracor, Inc. e mais »

Sunovion Celebrates Five-Year Anniversary Milestone Business Wire (press release) MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) announced today that it is celebrating its five-year anniversary. Sunovion was established in October 2010 following the integration of Sepracor Inc. and Dainippon ... e mais »

Drugmaker Sepracor Accepts $2.6B Buyout Offer from Japan's Dainippon Xconomy In what could become Massachusetts' largest life science deal of the year, Marlborough, MA-based drugmaker Sepracor (NASDAQ:SEPR) has agreed to be acquired by the Japanese pharmaceutical firm Dainippon Sumitomo Pharma for a whopping $2.6 ... e mais »

Psychiatric Implications of Neurological Disorders: May 2017 Healio Andrew A. Nierenberg, MD, has disclosed the following relevant financial relationships: Appliance Computing Inc. (Mindsite); Astra Zeneca; Brain Cells, Inc.; Brandeis University; Bristol Myers Squibb; Clintara, Dianippon Sumitomo/Sepracor; Eli Lilly ...

CoLucid Pharmaceuticals Announces Election of Mark Corrigan, MD, to Board of Directors GlobeNewswire (press release) Dr. Corrigan was Executive Vice President, Research & Development of Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.) from April 2003 until December 2009. Prior to joining Sunovion Pharmaceuticals, he spent 10 years with Pharmacia & Upjohn, Inc. e mais »

POZEN Announces Retirement of Founder, Chairman and CEO Dr. John R. Plachetka; Adrian Adams Named as CEO Business Wire (press release) Prior to joining Sepracor, Mr. Adams was President and Chief Executive Officer of Kos Pharmaceuticals, Inc. until its acquisition by Abbott Laboratories. Mr. Adams has also held general management and senior international and national marketing ... e mais »

Crain's Detroit Business

Detroit-based Trimaran Pharma attracts experienced executives Crain's Detroit Business based Sepracor Inc. when it launched Lunesta, an insomnia drug that was later named by Forbes Magazine as the fifth most successful launch in pharma history, eventually surpassing $1 billion in annual sales. Piskorski also has startup experience.

Boston Globe

FDA approves Marlborough company's epilepsy drug Boston Globe An epilepsy tablet made by Marlborough-based Sunovion Pharmaceuticals Inc. won US approval Friday to be sold as a primary therapy for hundreds of thousands of Americans suffering from partial-onset seizures. The drug, called Aptiom, has been on the ... e mais »

PMLiVE

Astellas appoints ethics and compliance and US legal leaders PMLiVE Wanda brings over 20 years of experience in the pharmaceutical industry, having held senior leadership positions at Schering-Plough and Sepracor Inc, a US-based biopharmaceutical company. Prior to joining Astellas as deputy general counsel and head of ...

Sunovion Pharmaceuticals Canada Inc. Announces Company Name Change Canada NewsWire (press release) Sepracor Pharmaceuticals, Inc. changes name, maintains commitment to developing scientifically-advanced central nervous system, cardiovascular disease and infectious disease therapies that improve patients' lives. MISSISSAUGA, ON, Aug. 17, 2011 ... e mais »

Envisia Therapeutics Appoints William Yelle Executive Chairman PR Newswire (press release) Prior to Aldea, Yelle was Senior Vice President of Corporate Development for Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.). While at Sepracor, he was instrumental in the company's transition from an early stage clinical organization into a ... e mais »

CEO Adrian Adams Is Prepping Aralez For A Sale Seeking Alpha Aralez has an approval for Yosprala, a revenue-generating set of products, and two acquisitions that can make it money. Its bull thesis considers those as positives while the bear focuses on the debt that goes with the package. CEO Adrian Adams, with a ...

Hants Journal

Windsor pharmaceutical company closing mid-2013 Hants Journal A pharmaceuticals plant in Windsor is slated for closure in mid-2013. Sunovion Pharmaceuticals Inc., the Massachusetts-based parent company of Sepracor Canada Ltd., released a prepared statement to the media Dec. 5 to inform the public of the closure, ... Shutdown at Windsor drug plant will cost 32 jobsTheChronicleHerald.ca todos os 8 artigos de notícias »

Cabot Corporation Names New Vice President of Investor Relations Business Wire (press release) Prior to joining Cabot, Mr. Delahunt held several senior financial positions including Vice President and Treasurer for Sepracor Inc. and Vice President and Treasurer for PerkinElmer, Inc. Delahunt earned his MBA and BS in Business Administration from ... e mais »

Flex Pharma Announces Executive Leadership Transition Business Wire (press release) Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases including amyotrophic lateral sclerosis (ALS ... e mais »

Agilis Biotherapeutics Expands Commercial, Medical Teams Business Wire (press release) BUSINESS WIRE)--Agilis Biotherapeutics, Inc. (Agilis), a biotechnology company advancing innovative gene therapy products for the treatment of rare genetic diseases that affect the central nervous system (CNS), announced today that the Company has ... e mais »

Boston Globe

Sunovion gets OK for its epilepsy drug Boston Globe It was the second drug approval in the past five months for Sunovion, a company formerly known as Sepracor Inc. that was purchased for $2.6 billion in 2009 by Japan's Dainippon Sumitomo Pharma Co. In June, the Marlborough company won FDA approval ... e mais »